New Retina Radio By Eyetube

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report. This editorially independent podcast is supported with advertising.

How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.  This editorially independent podcast is supported with advertising.

DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.  This editorially independent podcast is supported with advertising.

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.  This editorially independent podcast is supported with advertising.

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session. This editorially independent podcast is supported with advertising.

In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?  This editorially independent podcast is supported with advertising.

This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?  This editorially independent podcast is supported with advertising.

NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.  This editorially independent podcast is supported with advertising.

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).  This editorially independent podcast is supported with advertising.

The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year’s AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.  This editorially independent podcast is supported with advertising.

New Retina Radio’s John Kitchens, MD, and Jorge Fortun, MD, introduce the premier episode of New Retina Radio Journal Club, a new series dedicated to reviewing the latest papers and how they relate to day to day clinical practice. In this episode, Dr. Fortun is joined by Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, to discuss two papers that address the role, or lack thereof, of anti-VEGF therapy in the treatment of neovascular age-related macular degeneration and geographic atrophy. This editorially independent podcast is supported with advertising.

In this podcast, Prof. Bart Leroy (Belgium), Prof. Isabelle Audo (France) and Prof. Robert Maclaren (UK) discuss the management of patients with inherited retinal diseases (IRDs), from the initial identification of a patient with an IRD and referral to specialist center, through to the confirmation of a diagnosis using genotyping and the long-term implications for the patient of receiving that diagnosis. They discuss the current treatment landscape for patients with IRDs and outline future potential therapies on the horizon. This editorially independent podcast is supported with advertising.

Arming patients with knowledge is key to fighting any disease. What happens when a confluence of factors create a breeding ground for an uneducated patient population? John W. Kitchens, MD (United States), is joined by Patricio Schlottmann, MD (Argentina), Nicole Eter, MD (Germany), and Adnan Tufail, MBBS, MD, FRCOphth (United Kingdom) to review tactics for educating patients and battling misinformation in the COVID-19 era. This editorially independent podcast is supported with advertising.

The COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandemic. Also, Dr. Kitchens asks the panel how they’ve handled educating patients about the pandemic—and how they’ve tackled questions of misinformation.  This editorially independent podcast is supported with advertising.

Telemedicine has been put to the test during the COVID-19 pandemic. How is it holding up—and just how effective will it be going forward? John W. Kitchens, MD (United States), is joined by Francesco Boscia, MD (Italy); David Steel, MBBS, FRCOphth (United Kingdom); and Ramin Tadayoni, MD, PhD (France), to discuss how much telemedicine has delivered as promised. This editorially independent podcast is supported with advertising.

The internal regulations governing academic institutions were tested during the COVID-19 surges of spring and summer. As we move into autumn, how effective have they been—and are any worth revisiting? New Retina Radio host John Kitchens, MD, reviews this topic with Dilraj Grewal, MD, from the Duke Eye Center; Adrienne Scott, MD, from the Wilmer Eye Institute; and Elliott Sohn, MD, from University of Iowa to gain a better understanding of how institutional safeguards kept patients and staff safe, and how they may have served as (sometimes necessary) roadblocks to getting practice back to pre-pandemic levels.  This editorially independent podcast is supported with advertising.

The disruptions to clinical and surgical workflows during the COVID-19 crisis are obvious. Less apparent are the downstream effects of adjustments to educational experiences. New Retina Radio host John Kitchens, MD, invites three leaders in academic retina—Sophie Bakri, MD, of the Mayo Clinic; Julia Haller, MD, of Wills Eye Hospital; and R.V. Paul Chan, MD, MSc, MBA, of the University of Illinois at Chicago—to discuss how training and selection of fellows has been altered during the COVID-19 pandemic, and to review the tactics their institutions have employed to mitigate the interference their programs have endured. This editorially independent podcast is supported with advertising.